Intra-Cellular Therapies Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020
Revenue	346.62	290.42	226.9	176.78	118.1	87.53
Revenue Growth (YoY)	46.40%	27.99%	28.35%	49.69%	34.92%	-
Cost of Revenue	224.79	182.65	140.12	109.31	71.84	53.91
Gross Profit	121.83	107.77	86.78	67.47	46.26	33.62
Selling, General & Admin	63.78	58.25	51.3	39.22	28.24	28.47
Other Operating Expenses	11.1	9.54	7.79	6.43	4.14	-0.16
Operating Expenses	81.64	73.61	63.46	49.24	36.35	28.31
Operating Income	40.19	34.16	23.32	18.23	9.91	5.32
Interest Expense	-2.66	-1.46	-0.48	-0.48	-0.57	-
Interest & Investment Income	0.73	0.73	0.31	0	0.01	0.01
Other Non Operating Income (Expenses)	-0.04	0.01	-0	-1.74	-0.17	-
EBT Excluding Unusual Items	38.22	33.44	23.15	16.01	9.17	5.33
Merger & Restructuring Charges	-0.86	-1.22	-	-	-	-
Gain (Loss) on Sale of Assets	0.12	0.12	0.05	0.07	-0.13	0.02
Pretax Income	37.49	32.34	23.2	16.08	9.04	5.35
Income Tax Expense	11.32	9.98	7.12	4.97	2.53	1.38
Net Income	26.16	22.36	16.08	11.12	6.51	3.98
Net Income to Common	26.16	22.36	16.08	11.12	6.51	3.98
Net Income Growth	48.66%	39.11%	44.64%	70.79%	63.72%	-
Shares Outstanding (Basic)	103	96	86	77	63	-
Shares Outstanding (Diluted)	104	97	87	78	63	-
Shares Change (YoY)	17.89%	11.34%	11.37%	22.92%	-	-
EPS (Basic)	0.25	0.23	0.19	0.14	0.10	-
EPS (Diluted)	0.25	0.23	0.18	0.14	0.10	-
EPS Growth	25.91%	24.87%	29.37%	38.84%	-	-
Free Cash Flow	37.39	21.66	5.26	9.2	9.62	9.54
Free Cash Flow Per Share	0.36	0.22	0.06	0.12	0.15	-
Dividend Per Share	0.126	0.108	0.093	0.037	0.050	0.036
Dividend Growth	35.48%	16.13%	151.35%	-26.15%	37.26%	-
Gross Margin	35.15%	37.11%	38.25%	38.17%	39.17%	38.41%
Operating Margin	11.60%	11.76%	10.28%	10.31%	8.39%	6.07%
Profit Margin	7.55%	7.70%	7.08%	6.29%	5.51%	4.54%
Free Cash Flow Margin	10.79%	7.46%	2.32%	5.20%	8.15%	10.90%
EBITDA	42.14	36	24.75	19.28	11.02	6.53
EBITDA Margin	12.16%	12.39%	10.91%	10.91%	9.33%	7.46%
D&A For EBITDA	1.94	1.83	1.43	1.05	1.11	1.22
EBIT	40.19	34.16	23.32	18.23	9.91	5.32
EBIT Margin	11.60%	11.76%	10.28%	10.31%	8.39%	6.07%
Effective Tax Rate	30.20%	30.85%	30.70%	30.89%	28.02%	25.70%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.